Research programme: neuropeptide FF receptor antagonists - Juvantia Pharma
Alternative Names: Neuropeptide FF receptor antagonists research programme - Juvantia PharmaLatest Information Update: 04 Sep 2020
At a glance
- Originator Juvantia Pharma
- Class
- Mechanism of Action Neuropeptide FF receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 20 Jul 2005 This programme is still in active development - (BIO-2005)
- 19 Jan 2001 Preclinical development for Pain in Finland (Unknown route)